FY2024 Earnings Estimate for MOLN Issued By Leerink Partnrs

Molecular Partners AG (NASDAQ:MOLN) – Investment analysts at Leerink Partnrs issued their FY2024 earnings estimates for Molecular Partners in a research note issued on Thursday, March 6th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings per share of ($1.93) for the year. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners’ Q4 2024 earnings at ($0.45) EPS and FY2025 earnings at ($1.71) EPS.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%.

Separately, Lifesci Capital began coverage on shares of Molecular Partners in a research note on Tuesday. They issued an “outperform” rating and a $12.00 target price for the company.

Molecular Partners Stock Performance

MOLN stock opened at $4.62 on Monday. The stock has a market capitalization of $186.28 million, a P/E ratio of -2.15 and a beta of 1.06. Molecular Partners has a one year low of $3.32 and a one year high of $12.70. The company has a 50 day moving average price of $5.09 and a two-hundred day moving average price of $5.33.

Institutional Trading of Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL boosted its position in Molecular Partners AG (NASDAQ:MOLN) by 205.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,353,968 shares of the company’s stock after acquiring an additional 910,747 shares during the period. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent reporting period. Institutional investors own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.